Liquid formulations for TNFR:Fc fusion proteins
US9649383B2 · kind B2 · utility
7Cited by
2References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 15, 2013 |
| Grant date | May 16, 2017 |
| Priority date | — |
| Expiry date | Nov 15, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.